One of the most pressing needs in clinical oncology today is for a system which will allow selection of the most effective chemotherapeutic agent against an individiual patient's tumor. The human tumor cloning system is such a system which has the potential for predicting which drug will or will not work against a particular patient's tumor. Despite considerable experience with conventional two layer soft agar system currently utilized to clone human tumors, there are still a variety of problems which plague the system. Chief problems with the two layer soft agar system include inability to grow th majority of patients tumors, low plating efficiencies, the need for very large numbers of tumor cells, tremendous technical time and expense for plating and counting, and the lack of flexibility of the system for utilizing different drug schecules or combinations of drugs. In this renewal application, we propose to develop a new system called the perfused capillary clonging system which has the potential for solving most of these problems. The system is based on the fact that cells growing in a smaller vessel (i.e., a capillary tube) have a higher cloning efficiency than cells growing in 35 mm petri dishes. Thus these capillaries encourage higher plating efficiencies, require fewer cells, have higher percentages of tumors that grow, and require less time and materials for preparation and counting. Also important to the system are the use of special pourous capillary tubes (with a variety of pore sizes available) which can be inserted into a tube and perfused with media containing drugs (single agents or combinations). This perfusion system allows total flexibility for drug scheduling and in vitro combination chemotherapy studies. Overall, this new perfused capillary cloning system should make cloning of human tumors a far more useful and practival tool for drug sensitivity testing as well as for study of human tumor biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA027733-05
Application #
3167789
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1980-07-15
Project End
1986-12-31
Budget Start
1985-01-01
Budget End
1985-12-31
Support Year
5
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Von Hoff, D D; Sandbach, J F; Clark, G M et al. (1990) Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:110-6
Von Hoff, D D (1990) He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82:96-101
Hanauske, A R; Osborne, C K; Chamness, G C et al. (1987) Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 23:545-51
Von Hoff, D D (1987) In vitro predictive testing: the sulfonamide era. Int J Cell Cloning 5:179-90
Harris, G J; Von Hoff, D D (1986) Drug sensitivity testing of carcinoma of the gallbladder and biliary tree in a human tumor cloning assay. Cancer Drug Deliv 3:197-204
Harris, G J; Turner, J N; Von Hoff, D D (1986) Growth of carcinoma of the esophagus and gastroesophageal junction in a human tumor cloning assay. Cancer Drug Deliv 3:273-8
Morris, G L; Zeltzer, P M; Schneider, S L et al. (1986) Cloning of pediatric malignancies for drug sensitivity testing in the human tumor cloning assay. Am J Pediatr Hematol Oncol 8:52-7
Scheithauer, W; Von Hoff, D D; Forseth, B et al. (1986) Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay. Cancer Drug Deliv 3:15-24
Von Hoff, D D; Clark, G M; Weiss, G R et al. (1986) Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4:1827-34
Hanauske, A R; Hanauske, U; Von Hoff, D D (1985) The human tumor cloning assay in cancer research and therapy: a review with clinical correlations. Curr Probl Cancer 9:1-66

Showing the most recent 10 out of 12 publications